CANCER IMMUNOTHERAPY INDEX
The Index Committee
The Cancer Immunotherapy Index is overseen by a committee of advisors who have experience in business and biotechnology. The role of the Committee is to ensure that the index is being managed professionally and according to its stated rules and objectives. Furthermore, the Committee may periodically review the index's methodology, vote on rule changes, and use their industry expertise to determine which stocks qualify to be considered as a cancer immunotherapy company. The Committee formally meets before each semi-annual rebalance/reconstitution date, and communicates informally throughout the year as other issues arise. The Committee members are:
Steve Dickman - CEO of CBT Advisors. CBT Advisors (www.cbtadvisors.com) is a life sciences consulting firm in Cambridge, Massachusetts, that works with public and private biotechnology firms as well as top-tier VC funds. Mr. Dickman has twelve years of experience providing strategic analysis on behalf of clients in the biotechnology industry. He is a former venture capitalist with TVM Capital, a former writer with Nature and The Economist, and a current contributor to Forbes. He also carried out biochemistry research at Princeton University and the German Cancer Research Center.
Brad Loncar - Owner of Loncar Investments. Mr. Loncar is an independent biotechnology industry investor and has managed a biotech-focused family portfolio from his Lenexa, Kansas office since 2008. He previously worked in the financial services industry at Franklin Templeton Investments, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury. Mr. Loncar currently writes biotechnology commentary at www.LoncarBlog.com and has contributed opinion pieces to Endpoints News and Xconomy.com.
Paul Rennert - President & CSO of Aleta Biotherapeutics and Founder & Principal of Sugarcone Biotech LLC. Paul's industry expertise covers bench to clinical trial development of diverse therapeutics for oncology, autoimmunity, inflammation and fibrosis (Repligen and Biogen). Since 2012 he has been involved in the genesis of novel biotechnology companies, most recently as co-founder of Aleta. Aleta Biotherapeutics develops transformative technologies to advance adoptive cellular therapies for the treatment of diverse cancers. Paul has authored numerous publications and patents, and recently served as editor for the review volume "Novel Immunotherapeutic Approaches to the Treatment of Cancer".